Home/Filings/4/0000950170-25-084869
4//SEC Filing

Hsieh Ming 4

Accession 0000950170-25-084869

CIK 0001674930other

Filed

Jun 10, 8:00 PM ET

Accepted

Jun 11, 4:30 PM ET

Size

12.3 KB

Accession

0000950170-25-084869

Insider Transaction Report

Form 4
Period: 2025-06-09
Transactions
  • OtherSwap

    Forward sale contract (obligation to sell)

    2025-06-09800,0000 total(indirect: By Trust)
    Common Stock (800,000 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    7,895,115
  • Common Stock

    (indirect: By Trust)
    220,816
  • Common Stock

    810,679
  • Common Stock

    (indirect: Uniform Transfer to Minor Account)
    1,000
  • Common Stock

    (indirect: Uniform Transfer to Minor Account)
    1,000
Hsieh Ming
DirectorChief Executive Officer10% Owner
Transactions
  • OtherSwap

    Forward sale contract (obligation to sell)

    2025-06-09800,0000 total(indirect: By Trust)
    Common Stock (800,000 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    220,816
  • Common Stock

    (indirect: Uniform Transfer to Minor Account)
    1,000
  • Common Stock

    (indirect: By Trust)
    7,895,115
  • Common Stock

    (indirect: Uniform Transfer to Minor Account)
    1,000
  • Common Stock

    810,679
Footnotes (5)
  • [F1]Securities held by The Ming Hsieh Trust (the "Trust"). Mr. Hsieh is the trustee of the Trust and possesses the sole voting and dispositive power with respect to securities held by the Trust.
  • [F2]Securities held by the Dynasty Trust. Mr. Hsieh is the grantor of the Dynasty Trust and he and his spouse, Eva Hsieh, and Jian Xie serve on the investment committee of the Dynasty Trust. Mr. Hsieh disclaims any beneficial interest except with respect to any pecuniary interest therein.
  • [F3]Shares held in a Uniform Transfers to Minor Act account for which Ming Hsieh acts as custodian and possesses the sole voting and dispositive power.
  • [F4]Previously, on September 14, 2022, the Trust entered into a prepaid variable forward agreement (the "2022 Agreement") with an unaffiliated bank (the "Bank"). The 2022 Agreement obligated the Trust to deliver up to 800,000 shares of the issuer's common stock, $0.0001 par value per share ("Common Stock") (or, at the Trust's election, an equivalent amount of cash) to settle the 2022 Agreement.
  • [F5]On June 9, 2025, the Trust elected to cancel the 2022 Agreement with respect to all 800,000 shares. In connection with the cancellation, the Trust paid an aggregate of $16,446,960.00 to the Bank. Following the payment and cancellation described above, the 800,000 shares held by the reporting person that were previously subject to the prepaid forward contract are no longer pledged to the Bank.

Documents

1 file

Issuer

Fulgent Genetics, Inc.

CIK 0001674930

Entity typeother

Related Parties

1
  • filerCIK 0001302110

Filing Metadata

Form type
4
Filed
Jun 10, 8:00 PM ET
Accepted
Jun 11, 4:30 PM ET
Size
12.3 KB